Julian Adams, Ph.D., is President of Research and Development. Prior to joining Infinity, Dr. Adams was the Senior Vice President, Drug Discovery and Development at Millennium Pharmaceuticals. In this capacity, he had global responsibility for multiple drug discovery programs, including the successful discovery and development of VELCADE®, a proteasome inhibitor for cancer therapy. He joined Millennium through its acquisition of LeukoSite in 1999 where he was Senior Vice President, Research and Development. Dr. Adams joined LeukoSite as a result of its acquisition of ProScript, Inc., where he had served as a member of the founding management team, Executive Vice President of Research and Development, and a member of the Board of Directors. Earlier in his career, Dr. Adams served in various positions, including Director, Medicinal Chemistry at Boehringer Ingelheim, where he successfully discovered the drug Viramune® for HIV. Also, from 1982-1987, he was a Medicinal Chemist at Merck.

Dr. Adams received a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry. He has received many awards, including the 2001 Ribbon of Hope Award for VELCADE® from the International Myeloma Foundation. Dr. Adams is an inventor of over 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals. He is the editor of Proteasome Inhibition in Cancer Therapy published in July 2004.

Michael S. Curtis, Ph.D., is Vice President of Pharmaceutical Development with responsibility for manufacturing, formulation, and analytical characterization of Infinity's pre-clinical and clinical drug candidates. Prior to joining Infinity, Dr. Curtis was an Associate Director within the Pharmaceutical and Analytical Development group at Transkayotic Therapies (TKT, currently Shire) where he was responsible for analytical methods development and validation to support the registration of Elaprase® (idursulfase). Before TKT, Dr. Curtis was the Associate Director of Analytical Development at Syntonix Pharmaceuticals where he was involved with advancing the Transceptor® drug delivery technology and in particular its expansion as an oral delivery platform. Prior to Syntonix, he was a member of the Therapeutic Protein Research group at Genzyme working on the development and characterization of the enzyme replacement therapy Myozyme® (alglucosidase alfa). Dr. Curtis began his career at Bristol-Myers Squibb where he held positions of increasing responsibility working in small molecule and biologics development, most significantly on the manufacturing processes for Capoten® (captopril) and Taxol® (paclitaxel) and the early development of Orencia® (abatacept).

Dr. Curtis received his B.S. in Biochemistry from the State University of New York College of Environmental Science and Forestry and his Ph.D. in Cell and Molecular Biology from Upstate Medical University.

John J. Keilty , is Vice President, Information Technology and Informatics. Mr. Keilty is responsible for information systems, software development, structural biology, bioinformatics, and clinical informatics. Prior to joining Infinity, Mr. Keilty was an early member of Millennium Pharmaceuticals where he held various roles of increasing responsibility, including Senior Manager of Molecular Research Services with broad ownership for the creation, management, implementation and transfer of much of the company’s core genomic technologies. Many of the developed software applications, algorithms and laboratory procedures were transferred to Millennium’s corporate partners as part of larger business collaborations. Before Millennium, Mr. Keilty worked in the Howard Hughes lab of Michael Green at University of Massachusetts Medical Center, focusing on basic research in transcription and gene splicing.

Mr. Keilty holds a B.A. in biology from Clark University and a M.S. in Bioinformatics from Brandeis University.

Jeanette W. Kohlbrenner, is Vice President, Human Resources. She is responsible for Infinity’s human resource and organizational development functions. Ms. Kohlbrenner joined Infinity with over 15 years of experience in senior human resource roles with life science and medical device companies, ranging from start-up to fully commercial, global organizations. Prior to joining Infinity, Ms. Kohlbrenner was the Business Unit Director of Human Resources for Cambrex Biosciences, with responsibilities for pharmaceutical development and manufacturing locations in the United States. Before Cambrex, Ms. Kohlbrenner was at Syntonix Pharmaceuticals, where she was the Director of Human Resources and a key member of the senior team, working to build the company. Ms. Kohlbrenner also held human resource roles with Genetics Institute/Wyeth Pharmaceuticals, and Hewlett-Packard’s Medical Device business (now Philips Medical). Early in her career, Ms. Kohlbrenner was a compensation and performance management consultant with William Mercer, a global leader in human resource consulting.

Ms. Kohlbrenner holds an M.B.A. from Babson College and a B.A. in Mathematics from Holy Cross.

Christopher M. Lindblom, CPA, is Vice President and Controller. He is responsible for financial reporting, accounting, financial planning, treasury, tax and insurance. Prior to joining Infinity in 2006, Mr. Lindblom served as Assistant Controller at Millennium Pharmaceuticals, with broad ownership in accounting, including VELCADE® and Sarbanes-Oxley compliance. Before Millennium, Mr. Lindblom held various financial planning and SEC reporting roles at Parametric Technology Corporation and Harcourt General, Inc. Mr. Lindblom began his career at PricewaterhouseCoopers in Boston, where he worked with a variety of public and private audit clients.

Mr. Lindblom holds a M.B.A. from Boston College and a B.S. in Accounting from Syracuse University. Mr. Lindblom is a certified public accountant.

Vito J. Palombella, Ph.D., is Chief Scientific Officer. Prior to joining Infinity, Dr. Palombella was at Syntonix Pharmaceuticals. At Syntonix he was Director of Molecular Biology and Protein Chemistry, responsible for improving and expanding its core Fc receptor-mediated drug delivery technology. Before joining Syntonix, Dr. Palombella was Senior Director of Cell and Molecular Biology at Millennium Pharmaceuticals, which he joined through its acquisition of LeukoSite (where he held the same title) in 1999. Prior to its acquisition by LeukoSite, Dr. Palombella held a number of positions at ProScript, Inc. (between 1994 and 1999). While at ProScript, LeukoSite, and Millennium, Dr. Palombella was involved in the discovery and development of VELCADE®, a proteasome inhibitor for cancer therapy. He also managed a number of additional projects, including research into NF-κB regulation.

Dr. Palombella received a B.S. in Microbiology from Rutgers University and his M.S. and Ph.D. in Viral Oncology and Immunology from the New York University Medical Center. He was also a post-doctoral fellow at Harvard University in the laboratory of Dr. Tom Maniatis.

Adelene Q. Perkins, is President and Chief Executive Officer.

Ms. Perkins has over 25 years of international business and corporate strategy experience in the biopharmaceutical industry, focused on licensing and business development, strategic finance, product life cycle management, and leading high-caliber, cross-functional teams. Since joining Infinity as Chief Business Officer in 2002, she has played an integral role in developing Infinity's strategic plan, leading the company in its transition from a platform to a product-based organization. She has also been the principal figure in structuring, executing and managing all of Infinity's innovative strategic relationships, including its global alliance with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. Ms. Perkins served as President and Chief Business Officer of Infinity from 2008-2009 prior to becoming President and Chief Executive Officer in 2010.

Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as Vice President of Business and Corporate Development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Wyeth, where she was Vice President of Emerging Businesses and the cofounder and General Manager of the DiscoverEase™ Business Unit. She also formed and served as Chief Executive Officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University directed at discovering and developing members of the TGF-b superfamily. She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives and was responsible for numerous business development transactions, including both in- and out-licensing technologies and products.  From 1985-1992, Ms. Perkins was at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry.

Ms. Perkins holds an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from Villanova University. She is on the Board of Project Hope and the Villanova University College of Engineering Advisory Board.

Gerald E. Quirk, Esq., is Vice President, Corporate Affairs and General Counsel.  He is responsible for investor and public relations, government affairs, corporate governance, finance and accounting, intellectual property and legal affairs.  Prior to joining Infinity in 2006, Mr. Quirk served in a number of progressively responsible legal and business development positions at Genzyme Corporation, where he led licensing and corporate partnering, M&A, merger integration and financing activities for several business units, and served on the launch team for Clolar® (clofarabine).  Mr. Quirk began his career as an associate in the business law department and biotechnology practice group at Palmer & Dodge LLP, a Boston law firm.  Mr. Quirk is a frequent speaker on the relationship between industry and academia in the drug development process.

Mr. Quirk earned his J.D. from Northeastern University School of Law, an Ed.M. in Educational Administration from Harvard University, and a B.A. in Political Science from Swarthmore College.

Tamyra Toole, Esq., is Vice President, Regulatory Affairs and Quality Assurance with responsibility for the global regulatory activities and strategy for the development of Infinity’s drug candidates, and corporate compliance with Good Manufacturing Practices, Good Clinical Practices and Good Laboratory Practices. Ms. Toole oversees Infinity’s government regulations, guidelines, and policies. Prior to joining Infinity, Ms. Toole was the Senior Director, Regulatory Affairs at NitroMed, Inc. and has previously held positions in regulatory affairs and quality assurance at Wyeth Pharmaceuticals, Millennium Pharmaceuticals and Organogenesis, Inc. She has experience developing drugs, biologics and medical devices in the oncology, hematology, cardiovascular, and plastic and reconstructive therapeutic areas. Prior to working in drug development, Ms. Toole held various positions in the Department of Nursing at Brigham and Women’s Hospital.

Ms. Toole holds a J.D. from the Catholic University of America, Columbus School of Law and a B.S. in Nursing from Villanova University.

Winselow S. Tucker, Jr. is Vice President, Marketing. Mr. Tucker is responsible for bringing commercial insights to the company’s product development decisions and business development initiatives, as well as leading Infinity’s new product marketing activities. Mr. Tucker has 15 years of comprehensive commercial pharmaceutical experience in sales, new product marketing and brand leadership in both global and country level positions across a number of therapeutic areas. Prior to joining Infinity in 2010, Mr. Tucker held roles of increasing responsibility at Novartis Pharmaceuticals in the US and Global operations; most recently at Novartis Oncology where he was the global brand leader for the company’s Gleevec® (imatinib) and Tasigna®(nilotinib) franchise. At Novartis, Mr. Tucker also led launch for those products in several oncology indications.

Mr. Tucker also possesses strong brand leadership experience having led the U.S. launch of Tasigna, successfully integrating the product into the Novartis CML franchise, before going on to lead the Gleevec and Tasigna franchise in the U.S. Mr. Tucker joined Novartis Pharmaceuticals in Europe where he developed global marketing and launch strategies for a leading anti-hypertensive drug. Prior to Novartis, Mr. Tucker spent several years in commercial roles at GlaxoSmithKline Pharmaceuticals, where he played a critical role in the successful launch of a blockbuster diabetes drug and had responsibility for commercial decisions on a portfolio of new products in development across various indications and therapeutic areas.

Mr. Tucker holds a Bachelor’s degree in Business Administration from Howard University and an M.B.A. in Marketing from Indiana University.